Angiotensin II: Unraveling GPCR Signaling in AAA Pathogenesis

Introduction

Abdominal aortic aneurysm (AAA) represents a significant clinical challenge due to its insidious progression and high mortality rate upon rupture. While imaging remains the principal strategy for AAA detection and surveillance, the need for molecular insight into disease mechanisms is increasingly evident. Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe)—an endogenous octapeptide and potent vasopressor and GPCR agonist—has emerged as a pivotal molecular tool for mechanistic dissection of vascular pathophysiology, particularly in the context of hypertension, cardiovascular remodeling, and AAA development. Here, we examine recent advances in leveraging Angiotensin II for modeling AAA and elucidating the intertwined roles of angiotensin receptor signaling, vascular smooth muscle cell (VSMC) hypertrophy, and cellular senescence.

Angiotensin II: Biochemistry and Experimental Utility

Angiotensin II (CAS 4474-91-3) is synthesized from angiotensin I via the angiotensin-converting enzyme (ACE) and exerts its effects primarily through angiotensin II type 1 (AT1) and type 2 (AT2) receptors, both members of the G protein-coupled receptor superfamily. Its sequence, Asp-Arg-Val-Tyr-Ile-His-Pro-Phe, confers high-affinity receptor binding (IC₅₀ typically 1–10 nM), with downstream activation of phospholipase C, IP3-dependent calcium release, and protein kinase C pathways. These signaling events mediate vasoconstriction, aldosterone secretion, and renal sodium reabsorption, thus tightly regulating blood pressure and volume homeostasis.

Experimentally, Angiotensin II is both soluble (≥234.6 mg/mL in DMSO, ≥76.6 mg/mL in water) and stable under standard laboratory storage (-80°C), making it highly amenable for in vitro and in vivo models. In vitro, exposure of VSMCs to 100 nM Angiotensin II for 4 hours robustly increases NADH and NADPH oxidase activity, reflecting oxidative stress induction and hypertrophic signaling. For in vivo research, continuous infusion into C57BL/6J (apoE–/–) mice at 500–1000 ng/min/kg for 28 days reliably induces AAA, enabling investigation of vascular remodeling, inflammation, and rupture susceptibility.

Modeling AAA: Insights from Angiotensin II-Driven Pathways

The ability of Angiotensin II to recapitulate key features of human AAA in murine models has transformed research in vascular biology and disease. Upon chronic infusion, Angiotensin II promotes characteristic vascular changes—including medial degeneration, adventitial inflammation, and elastin breakdown—that mirror the human disease process. Notably, these pathological events are tightly coupled to angiotensin receptor signaling pathway activation in VSMCs and the vascular endothelium.

Central to this process is the cascade initiated by Angiotensin II-mediated phospholipase C activation, leading to IP3-dependent calcium release. This elevation in intracellular calcium serves as a second messenger for VSMC contraction, proliferation, and hypertrophy. Furthermore, downstream protein kinase C activation amplifies signaling for cytokine release and matrix metalloproteinase (MMP) expression, both of which contribute to vascular injury inflammatory response and structural remodeling.

Recent evidence also highlights the role of Angiotensin II in stimulating aldosterone secretion from adrenal cortical cells, which enhances renal sodium reabsorption. This not only perpetuates hypertension but also exacerbates hemodynamic stress on the aortic wall, fostering aneurysm development and progression.

Emerging Links: Senescence Genes and Angiotensin II in AAA

While the direct impact of Angiotensin II on VSMC hypertrophy and vascular inflammation is well-established, emerging studies have begun to elucidate its role in cellular senescence within the aneurysmal microenvironment. In a recent comprehensive analysis by Zhang et al. (Journal of Cellular and Molecular Medicine, 2025), high-throughput transcriptomic profiling and machine learning approaches identified key senescence-related genes (SRGs), including ETS1 and ITPR3, as diagnostic signatures for AAA.

Single-cell RNA sequencing and validation in both serum and mouse models revealed that senescent endothelial cells, characterized by upregulation of ETS1 and ITPR3, play instrumental roles in AAA progression. Notably, ITPR3 encodes the type 3 inositol 1,4,5-trisphosphate receptor, directly linking Angiotensin II-triggered IP3 signaling to the regulation of calcium homeostasis and, potentially, to senescence-associated phenotypes. These findings suggest that chronic Angiotensin II exposure not only drives canonical hypertrophy and inflammation but also modulates the senescence landscape, influencing vascular cell fate and aneurysm stability.

Practical Considerations for Angiotensin II Experimental Models

For researchers designing hypertension mechanism studies or cardiovascular remodeling investigations, reproducibility and optimization of Angiotensin II administration are paramount. Preparation of high-concentration stock solutions in sterile water (≥10 mM) and storage at -80°C ensures peptide integrity. In vivo, the use of osmotic or subcutaneous minipumps facilitates controlled, continuous delivery, with standard dosing regimens (e.g., 500–1000 ng/min/kg) having been validated for robust AAA induction in genetically susceptible mouse strains (e.g., apoE–/–).

Downstream analyses should encompass histopathological assessment of aortic architecture, quantification of inflammatory markers, and evaluation of senescence-associated gene expression in vascular tissue. Integration of single-cell transcriptomics and advanced imaging can further resolve cell-type-specific responses to Angiotensin II and uncover novel therapeutic targets.

Distinguishing Angiotensin II’s Role in AAA Versus Other Vascular Disorders

While Angiotensin II is widely recognized for its contributions to systemic hypertension and cardiac hypertrophy, its unique capacity to drive aneurysmal degeneration through a synergy of vasopressor action, GPCR-mediated signaling, and senescence induction sets it apart in vascular disease research. Unlike atherosclerosis models that rely on lipid dysregulation, the Angiotensin II-induced AAA model is characterized by a potent inflammatory milieu, elastin fragmentation, and marked upregulation of senescence-associated secretory phenotype (SASP) factors. This distinction is critical for researchers seeking to dissect the molecular underpinnings of aneurysm formation as opposed to generic vascular remodeling.

Future Directions: From Mechanistic Studies to Biomarker Discovery

The integration of Angiotensin II-driven models with high-throughput omics and machine learning is poised to accelerate discovery of early diagnostic biomarkers and therapeutic interventions for AAA. As demonstrated by the identification of ETS1 and ITPR3 as potential clinical markers (Zhang et al., 2025), unraveling the interplay between angiotensin receptor signaling and cellular senescence may inform both non-invasive diagnostics and targeted therapies. Moreover, further research into the modulation of phospholipase C activation, IP3-dependent calcium release, and aldosterone signaling could yield novel strategies to mitigate aneurysm progression.

Conclusion

Angiotensin II remains an indispensable tool in vascular biology, offering a robust platform for hypertension mechanism study, cardiovascular remodeling investigation, and the development of abdominal aortic aneurysm models. Its multifaceted actions—spanning GPCR agonism, induction of vascular smooth muscle cell hypertrophy, and regulation of senescence pathways—provide unique opportunities to interrogate disease mechanisms and identify translational biomarkers. The ongoing convergence of molecular signaling, advanced analytics, and experimental modeling promises to further illuminate the complexities of AAA and inform the next generation of vascular therapeutics.

Contrast with Existing Literature: This article extends beyond the cellular and mechanistic insights provided in Angiotensin II in Vascular Smooth Muscle Cell Hypertrophy... by synthesizing recent advances in senescence gene discovery, biomarker development, and translational modeling of AAA. While prior work has focused primarily on Angiotensin II’s direct effects on VSMC hypertrophy and GPCR signaling, the present piece uniquely integrates omics findings and highlights the diagnostic potential of senescence-related genes such as ETS1 and ITPR3, as identified via machine learning and single-cell analysis in AAA models.